|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To identify the genes that may participate in the development of APL, we analyzed data from an APL cDNA microarray (GSE12662) in the NCBI database, and found that ACTL6A was up-regulated in APL patients.
|
30448346 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whether SOX2 and ACTL6A/TP63 interact with the Hippo-YAP1 pathway in esophageal squamous cell carcinoma (ESCC) remains unclear.
|
31560173 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The ACTL6A expression level in fresh colon cancer specimens was also higher than that in the corresponding adjacent normal colon specimens.
|
30348114 |
2018 |
|
Acquired aplastic anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, gene expression analysis identified a significant loss of the SWI/SNF core component SMARCC1, along with ARID1B, ACTL6A, and SMARCD1, in human AA BM CD34<sup>+</sup> HSCs and hematopoietic stem and progenitor cells (HSPCs) compared with normal HSPCs.
|
29596882 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, our results suggested that BAF53A plays an important role in the expression of AR target genes in prostate cancer, and can be used clinically for the treatment of prostate cancer.
|
30278885 |
2018 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, our results suggested that BAF53A plays an important role in the expression of AR target genes in prostate cancer, and can be used clinically for the treatment of prostate cancer.
|
30278885 |
2018 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The ACTL6A expression level in fresh colon cancer specimens was also higher than that in the corresponding adjacent normal colon specimens.
|
30348114 |
2018 |
|
Colon adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, ACTL6A and p63 collaborate as oncogenic drivers in HNSCC.
|
28041841 |
2017 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Childhood Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Adult Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Cervix carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that BAF53 knockdown led to suppression of expression of E6 and E7 genes from HPV integrants in cervical carcinoma cell lines HeLa and SiHa.
|
21821000 |
2011 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ACTL6A promotes malignant behaviors of glioma cells in vitro and in orthotopic xenograft model.
|
29725063 |
2018 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that ACTL6A may contribute to cancer progression by stabilizing YAP/TAZ and therefore provide a novel therapeutic target for the treatment of human gliomas.
|
29725063 |
2018 |